DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Patent 6,699,871 protects JUVISYNC, JANUMET XR, JANUMET, JANUVIA, and STEGLUJAN, and is included in five NDAs.
Protection for JANUMET XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has seventy-four patent family members in forty-four countries.
Summary for Patent: 6,699,871
|Title:||Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes|
|Abstract:||The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.|
|Inventor(s):||Edmondson; Scott D. (New York, NJ), Fisher; Michael H. (Ringoes, NJ), Kim; Dooseop (Westfield, NJ), Maccoss; Malcolm (Freehold, NJ), Parmee; Emma R. (Scotch Plains, NJ), Weber; Ann E. (Scotch Plains, NJ), Xu; Jinyou (Scotch Plains, NJ)|
|Assignee:||Merck & Co., Inc. (Rahway, NJ)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Use;|
|Country||Patent Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|>Country||>Patent Number||>Estimated Expiration||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration|